Dividend Aristocrat Chemical Company Makes Best Dividend Stocks List As of today, Dividend.com is adding a chemical company to the Best Dividend Stocks list. This company has a 75-year operating history and is on the exclusive Dividend Aristocrat list – only companies in the S&P 500 that have raised their dividend for 25 consecutive years make the list. This chemical company produced almost $10 billion of revenue in 2016. In 2017, this company is expected to earn $6.25 per share, which would represent 9% year-over-year earnings growth. In 2018, the company is expected to grow earnings another 7.36%, to $6.71 per share. It has a long operating history and a proven track record of creating value for shareholders. In October 2016, the company completed the spin-off of one of its divisions, which represented almost 10% of the company's 2015 sales. 4 Reasons Why You Should Own This Stock: - You can get exposure to a chemical company that is a Dividend Aristocrat.
- With a payout ratio of around 62% and a 7.36% expected growth in the bottom line in 2018, the company is very likely to keep raising its dividend.
- The stock trades at 22.48 times projected 2017 earnings, which is fair valuation according to us given its stellar record of paying dividends.
- It has operations in over 50 countries, serves more than 30 industries and has 170,000+ customers worldwide.
| Stock Symbol | Unlock | | Price Recommended | Unlock | | Company Name | Unlock | | Date Recommended | 06/30/2016 | | DARS Rating | 3.9 | | Ex-Div Date | Unlock | | Current Yield | 2.65% | | Pay Date | Unlock | All data in table above updated as of 05/02/2017. UPGRADE TO UNLOCK THIS STOCK! MORE ABOUT THIS STOCK Trailing 5-Year Dividend Payout History - Annualized Growth Over Last 5 Years: 8.7%.
As a dividend investor, you need access to the best and safest stocks in the market. Dividend.com’s DARS ratings have been providing you with reliable and profitable stock analysis since 2008, and this addition is no exception. UPGRADE TO UNLOCK THIS STOCK! |
|
|
No comments:
Post a Comment